Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085644 · ClinicalTrials.gov registry record · Phase 3
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
NCT00085644 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 315 participants.
The verdict
NCT00085644, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL adalimumab (D2E7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085644
The ClinicalTrials.gov registry entry for NCT00085644 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00085644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085644 about?
NCT00085644 is a clinical study titled "Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis". The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NS...
What is the current status of trial NCT00085644?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2004-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00085644?
The interventions under investigation include: placebo (BIOLOGICAL), adalimumab (D2E7) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085644?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.